Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
26-week extension study of indacaterol in COPD
2008-000663-42Phase 3Completed
- Sponsor
- Novartis
- Start
- Mar 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of indacaterol in chronic obstructive pulmonary disease (COPD) (3 arms), sponsored by Novartis. Primary endpoint: Long-term safety after 52 weeks of treatment. Started Mar 2008; status: completed.
02
Drugs
indacaterol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2008-000663-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-000663-42.